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Abstract
Breast cancer is the most common cancer among women. To date, improvements in hormonal and cytotoxic therapies have
not yet led to a sustained remission or cure. In the present study, we investigated the in vitro and in vivo antitumor activities
of a novel Calotropis procera protein (CP-P) isolated from root bark. CP-P protein inhibited the proliferation and induced
apoptosis of breast cancer cells through the suppression of nuclear factor kappaB (NF-kB) activation. CP-P, when
administered individually or in combination with cyclophosphamide (CYC, 0.2 mg/kg) to rats with 7, 12-dimethyl
benz(a)anthracene (DMBA)-induced breast cancer decreased tumor volume significantly without affecting the body weight.
To elucidate the anticancer mechanism of CP-P, antioxidant activities such as superoxide dismutase (SOD), catalase (CAT),
glutathione-s-transferase (GST) and non-enzymatic antioxidant - reduced glutathione (GSH), vitamin E and C generation in
the breast were analyzed by various assays. SOD, CAT, GST, GSH, vitamin E and C levels were high in combination-treated
groups (CP-P+CYC) versus the CYC alone-treated groups. Also, the combination was more effective in down-regulating the
expression of NF-kB-regulated gene products (cyclin D1 and Bcl-2) in breast tumor tissues. Our findings indicate that CP-P
possesses significant antitumor activity comparable to a commonly used anticancer drug, cyclophosphamide, and may form
the basis of a novel therapy for breast cancer.
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Introduction
Breast cancer (BC) is one of the leading causes of death in
women worldwide [1] and ranked second after cervix and lung
cancer. Recently reported known risk factors, such as mammo-
graphic density [2], [3], [4], [5], genetic modifications of
interleukin-18 (IL-18) [6], tumor protein 53 (p53), breast cancer
1 (BRCA1) and breast cancer 2 (BRCA2) genes [7], [8], [9]
account for approximately 30% of breast cancer cases. However,
exposures to environmental chemicals like polycyclic aromatic
hydrocarbons (PAHs), obesity [10], and other life style-related
factors evidently play a pivotal role in this increased incidence
[11], [12]. Although breast cancer incidence has increased over
the past four decades, mortality has remained constant, due to the
vast improvement in detection and treatment options. However,
there is a relative lack of effective therapies for advanced-stage
metastatic disease. Thus, there is an urgent need to develop novel
therapeutic agents against advanced breast cancer, which are
expected to be safe and effective in this age class [1], [13].
Several agents derived from natural sources exhibit anti-cancer
properties without considerable adverse effects and play a vital role
for developing new drugs [14], [15], [16], [17], [18]. In addition,
epidemiological data suggest that consumption of plant foods or
natural products (47.2%) and botanical supplements (47.5%) [19],
which contain high levels of antioxidants, might slow down or
prevent the appearance of cancer [20]. Calotropis procera (L.) R.Br.
belongs to the family Asclepidaceae and is well known for its
various medicinal properties [21]. Different parts of leaves, roots,
flowers and latex from this plant are used in several Ayurvedic
systems of medicinal preparations [22]. The leaves of C. procera are
effective in treating migraines [23]. Leaves and stem bark extracts
of C. procera are widely used in Asian and West African traditional
therapy for dermatological and bronchial infections [24]. In
addition, the aqueous stem bark extract possesses cough-
suppresant activity against bronchial irritation caused by organic
solvent ammonia in Guinea pigs [25]. The decoction of the aerial
part of C. procera is commonly used in Saudi Arabian traditional
medicine for treating various diseases including fever, joint pain,
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muscular spasm and constipation. Ethanol extract of the plant has
been tested on laboratory animals for its antipyretic, analgesic,
antibacterial, anti-inflammatory, purgative [26], and muscle
relaxant activities [27]. The stem bark fractions of n-hexane, 1-
butanol, ethyl acetate, chloroform and water showed significant
anti-inflammatory activity at 200 and 400 mg/kg [28]. Addition-
ally, the root bark of C. procera has been found to produce marked
improvement in cases of diarrhoea and dysentery [29]. The effect
of an ethanolic extract of C. procera roots has been studied in albino
rats to explore its antifertility and hormonal activities [30]. Effects
of ethanol and aqueous extract from C. procera roots have also been
analyzed upon the oestrous cycle in rats [31].
The milky latex from this plant has been used in traditional
medicine to cure skin infections, poison, ulcer, enlargement of
spleen, liver, abdominal glands, colic piles, worms and different
inflammatory diseases [32]. Based on its traditional use, this latex
was selected for evaluation of its wound healing potential [24].
The clinical and pathological effects of C. procera latex have been
well investigated [33]. It showed mild toxic effects on heart, liver
and kidneys; that included multi-focal coagulation necrosis of
cardiac fibers and vacuolized hepatocytes [34]. Different proteins
like laticifer [35], and osmotin from the latex of C. procera
reportedly exhibit potent anti-fungal [36], antimycoplasmal [37],
anti-inflammatory [38], [39], insecticidal [40], larvicidal [41],
[42], antioxidant and radical scavenging activities [43], and
anticancer [44] properties. However, to date there is no literature
available for the anticancer effects of C. procera root bark. Because
Calotropis procera protein (CP-P) exhibits anti-inflammatory, anti-
oxidant, and antipyretic effects, we postulated that CP-P may
mediate its effects by modulating the NF-kB activation pathway.
The latter has been closely linked to inflammation, tumorigenesis,
proliferation, invasion, angiogenesis, and metastasis. The NF-kB
pathway is activated in response to various inflammatory agents,
carcinogens, tumor promoters, and growth factors. Hence, in the
present study we aim to investigate whether the antiproliferative/
pro-apoptotic in vivo effects of CP-P on 7, 12-dimethyl benz(a)an-
thracene (DMBA) induced breast cancer in rat models are
mediated through the suppression of NF-kB signaling pathway.
Our results indicate that CP-P inhibited the NF-kB activation
pathway and the expression of various antiapoptotic and
proliferative gene products, subsequently inducing apoptosis and
suppression of tumor growth in a DMBA-induced breast cancer
model.
Results
Identification of novel antitumor protein
A clear supernatant of C. procera extract was separated by gel-
filtration chromatography on Superdex G-75 column, yielding five
major peaks CP-1–CP-5 (Figure 1A). Fraction CP-3, showing the
highest recovery of total protein and antitumor activity, was
further fractionated by RP-HPLC on a C18 column and resolved
into two protein fractions, named CP-F1 and CP-F2 (Figure 1B).
CP-F1 was further applied to a HPLC reverse-phase (C8) column
and resolved into a single isolated protein CP-P (Figures 1C). The
mass of the pure protein was determined by MALDI-TOF/MS
(molecular weight 26156.19 kDa) (Figure 1D). The search
program MS-Fit and was used for searches in the database NCBI
BLAST and MSDB protein databases using Mascot tool. The
Mascot search results revealed that the protein (CP-P) matched a
previously reported apolipoprotein A-I protein (more details refer
to supplementary files in Table S1, S2).
In vitro cytotoxic effect of CP-P in breast cancer cells
We next investigated the effects of CP-P alone, or in
combination with CYC, on inhibition of growth and proliferation
of human MCF-7 and MDA-MB-231 breast cancer cells using
MTT and LDH bioassays. In single and combination treatments,
CP-P and CP-P+CYC inhibited cell growth and decreased cell
survival through induction of cell death in a dose-dependent
manner. The data revealed that MDA-MB-231 cells were more
sensitive to combination, versus single, treatment regimen
(P,0.01) (Figure 2A). The opposite relationship between the
LDH and MTT responses adds credence to the data accuracy. In
the LDH assay, as the concentration of the CP-P+CYC or CP-P
treatment increased, MCF-7 cells became progressively more
cytotoxic, leading to a greater absorbance reading in the LDH
assay and decreased absorbance in the MTT assay with a
concurrent decrease in the percentage of viable cells (Figure 2A).
In addition, the microscopic images clearly supported the findings,
as no changes were observed in untreated cells. In contrast, the
CP-P-exposed MCF-7 cells became necrotic after 24 h (Figure 2B).
The CYC-treated cells became round in shape. However, the
combination treatment completely damaged the breast cancer
cells. The ultra-structural examination demonstrated that the
untreated cells showed normal architecture (Figure 2C), MCF-7
cells exposed to CP-P showed cellular and morphological changes
that included cell death (Figure 2C). Standard drug CYC alone
also showed adverse effects on MCF-7 cells. Overall these
observations further confirmed that the combination treatment
of CP-P+CYC can induce MCF-7 cells death by apoptosis. MCF-
7 cells treated with CP-P+CYC showed apoptotic morphology
including chromatin condensation into dense granules or blocks.
The cells showed loss of microvilli and blebbing of cell membrane
which were characteristics of cells undergoing apoptosis
(Figure 2C).
CP-P induces apoptosis of breast cancer cells
We also investigated the apoptotic potential of CP-P apoptotic
potential in breast cancer cells. Cell cycle analysis was used to
analyze the distribution of MCF-7 cells in different phases of the
cell cycle following exposure to CP-P alone, or in combination
with CYC, after 24 h. We found that the apoptotic phase (Sub-G1
phase) was significantly increased in cells treated with CP-P+CYC
after 24 h. In addition, CP-P+CYC induced apoptotic effects were
statistically significant (**p value ,0.05) after 24 h (Figure 3A).
However, the accumulation of breast cancer cells in the Sub-G1
(apoptotic) phase increased only slightly after treatment with CP-P
and CYC at 24 h. The TUNEL assay showed the typical hallmark
morphological changes associated with apoptosis which includes
chromatin condensation, protein breakdown and DNA fragmen-
tation in the treated cells. The results showed a significant amount
of apoptotic cell death in the MCF-7 cells when compared with the
normal cells (Figure 3B, i–iv). Extensive cell death was observed in
proliferating human breast cancer cells after treatment with CP-P,
and in combination with CYC, through cytotoxic necrosis and
apoptosis.
CP-P inhibits TNF-a -dependent IkBa degradation and
phosphorylation
Because IkBa degradation is essential for the activation of NF-
kB [46], we determined whether inhibition of TNF-a -induced
NF-kB activation by CP-P was due to the inhibition of IkBa
degradation. We found that TNF-a -induced IkBa degradation in
control MCF-7 cells, but in CP-P-pretreated cells TNF-a had little
effect on IkBa degradation (Figure 3C). To determine whether the
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inhibition of TNF-a-induced IkBa degradation was due to
suppression in IkBa phosphorylation, we pretreated cells with
CP-P, exposed them to TNF-a, and then determined IkBa
phosphorylation levels in the cytoplasm by Western blot. TNF-a
induced IkBa phosphorylation while CP-P almost completely
suppressed it (Figure 3C, middle panel).
CP-P inhibits tumor necrosis factor (TNF-alpha)-induced
phosphorylation/translocation of p65
TNF-a induces the phosphorylation of p65, which is required
for transcriptional activity [45]. After phosphorylation, the p65
subunit is translocated to the nucleus. In the nuclear fraction from
the TNF-a -treated MCF-7 cells, there was a time-dependent
increase in the phosphorylated form of p65 that was suppressed by
CP-P. Western blot analysis also revealed that TNF-a induced
nuclear translocation of p65; and CP-P clearly suppressed its
translocation to the nucleus (Figure 3D, middle panel). The same
membrane was reblotted with PARP antibody to verify equal
loading. The results shown are representative of two independent
experiments
CP-P inhibits TNF-a -induced phosphorylation of IKK in
MCF-7 cells
TNF-a has been reported to activate TAK1 leading to the
phosphorylation of both IKK-a and IKK-b [47]. Whether CP-P
can modulate phosphorylation of IKK-a and IKK-b in breast
cancer cells was investigated. The results shown in Figure 3E
indicate that TNF-a induced the phosphorylation of both IKK-a
and IKK-b, and CP-P abolished TNF-a induced IKK activation.
CP-P represses the expression of TNF-a -induced NF-kB-
dependent gene products involved in proliferation and
survival
We next investigated whether CP-P can modulate the
expression of NF-kB -regulated gene products involved in the
proliferation and survival of tumor cells. Pretreatment with CP-P
inhibited TNF-a induced expression of cyclin D1 and Bcl-2 in
MCF-7 cells as observed by western blot analysis (Figure 3F). The
suppression of cyclin D1 and Bcl-2 may explain anti-proliferative
and pro-apoptotic activities of CP-P as described above.
Figure 1. Purification and characterization of anticancer protein CP-P. (A) The clear supernatant of Calotropis procera root-bark was
separated by gel-filtration (Superdex G-75) chromatography into five major peaks CP-1–CP-5, (B) the most active peak (CP-3) was further separated by
reverse-phase high performance liquid chromatography (RP-HPLC) by using a C18 column which produced two peaks namely CP-F1 and CP-F2, (C)
the active fraction (CP-F1) was resolved by a C8 column and gave a single peak named Calotropis procera protein ‘‘CP-P’’, (D) CP-P mass was analyzed
by a perspective biosystem matrix-assisted laser desorption ionization-time of flight (MALDI-TOF/MS).
doi:10.1371/journal.pone.0048514.g001
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Figure 2. The antiproliferative effect of CP-P evaluated against MCF-7 and MDA-MB-231 human breast cancer cells. (A) In vitro
cytotoxicity of CP-P, with or without CYC, upon MCF-7 and MDA-MB-231 cells at different doses (800–12.5 mg/ml). The CP-P alone, or when combined
with CYC, leads to significant (*P,0.01) reduction in cell proliferation even at 12.5 and 50 mg/ml doses versus untreated control. The MCF-7 cells were
more sensitive against the combination treatment. Values are mean 6 SD of three replicates. Untreated MCF-7 cells served as a control, CP-P
treatment evidenced cell death (CD) at 100 mg/ml concentrations on MDA-MB-231 cells. The CP-P alone, or in combination with CYC, caused the most
significant (*P,0.01) leakage of LDH. The combination treatment induced more cell-death and lytic effects in both cell lines than CP-P or CYC alone.
(B) Light micrographs showing the MCF-7 cell morphology before and after treatment. (i) There was no effect on untreated MCF-7 cells as a control,
(ii) protein (CP-P) or drug (CYC) alone treated cells induced severe cell membrane damage and inhibited MCF-7 cell growth, (iv) We also observed that
MCF-7 cells treated with CP-P in combination with CYC showed remarkable morphological changes like cell shrinkage, formation of membrane blebs,
nuclear and cytoplasmic condensation when observed under microscope (Symbol denotes: NC-Normal Control, MC-morphological changes, CD-Cell
Death, MD - membrane damage). (C) Electron micrographs of MCF-7 cells exposed to CP-P alone, or with CYC, showing the cellular and
morphological changes. The transmission electron microscopy (TEM) analysis was performed on MCF-7 human breast cancer cells exposed to the CP-
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In vivo antitumor activity of CP-P in rats
Each breast cancer control (BCC), rat received 1 mg of DMBA
that induced 100% multiplicity of mammary carcinomas during a
median latent period from 3 to 13 weeks (Figure 4A). The anti-
tumor effects of CP-P on DMBA-induced mammary carcinogen-
esis are shown. CP-P (0.2 mg/kg) when orally administered for 20
days suppressed DMBA-induced mammary gland carcinogenesis
in rats. In contrast, treatment with CP-P+CYC had significant
effects on mammary tumorigenesis after 3 weeks. Moreover, in
addition to the in vivo study showing a significant decrease in tumor
volume (Figure 4B), a significant increase in the life span of rats
was observed as compared to untreated group, the life span of CP-
P treated animals increased by 53.4% (0.2 mg/kg) and 73.9%
(CP-P 0.1 mg/kg)+CYC (0.1 mg/kg) effectively inhibited DMBA-
induced tumors in rats (Figure 4C). The tumor latency period was
calculated from the time at which 50% of the tumors had
appeared in the breast tumor control group. The CP-P alone or in
combination of CYC at 0.2 mg/kg, body weight doses exhibited
antitumor activity as revealed by the significant increase in mean
survival time and percent increase in life span of tumor-bearing
rats. However, the CYC treatment caused a significant decrease in
the body weight below the normal indicating toxicity (Figure 4D).
There was a lesser mammary tumor incidence in mice treated with
CYC alone versus BBC (p,0.05).
Histopathological analysis of CP-P treated tumor tissues
Histopathological examination revealed a clear architecture of
normal mammary glands (Figures 5A), whereas the breast cancer-
bearing rats showed severe tumor tissue necrosis and lesions
occurring after 13 weeks (90 days) of DMBA treatment (Figure 5B).
Thus, the CP-P individually treated group III rats showed a
reduction in the number of inflammatory cells (Figure 5C).
Whereas, the CYC alone treated rat group V also showed faster
epithelialization than the BCC treated rats (group II). In addition,
we found necrotic (ne), infiltration (i) of tissues by the chemother-
apeutic (CYC) effects on rats (Figure 5D). On the other hand,
histological evidence clearly proved the antitumor potential in
combination treated rats (groups IV) after 20 days (Figure 5E). In
addition, the images also showed that there was accelerated
epithelialization, tremendous reduction of infiltration and absence
of necrotic effects when compared to that of normal control rats
group I NF-kB is known to regulate the expression of number of
proteins, including those involved in proliferation (cyclin D1), and
survival (Bcl-2). Whether CP-P can modulate the expression of
these NF-kB-regulated gene products in tumor tissues, was
examined by western blot analysis. We found that treatment with
CP-P was effective in down regulating the expression of cyclin D1
and Bcl-2 in tumor tissues (Figure 5F).
Effect of CP-P on superoxide dismutase radical
scavenging activity (SOD)
Antioxidant enzyme levels were decreased in the BCC rats after
13 weeks (group II). The CP-P alone treated group (0.2 mg/kg)
(III) showed significantly (P,0.01*) elevated levels of SOD
following 20 days of oral treatment. The combination-treated
group (IV) exerted tremendous changes in SOD levels. Within the
CYC group (V), SOD led to pronounced level of increment as
compared to the NC (group I).
The GST levels were higher for the CP-P (group III)
individually-treated groups than the CP-P+CYC treatment group
(V) (Tables 1). The GST levels were significantly reduced in BCC
groups (group II), whereas CP-P-treated groups showed higher
levels of enzymatic antioxidant levels. In the CYC alone-treated
group IV, GST levels were significantly increased at 0.2 mg/kg
after 3 weeks. The enzymatic levels were not changed in the
control group (group I). The BCC rats (group II) showed
significant enzyme reduction after 13 weeks. However, CP-P
individually-treated groups (III) versus the CP-P+CYC group (V)
induced higher catalytic activity and suppressed the DMBA
action. The CYC alone-treated group (IV) showed higher levels of
CAT activity due to the presence of mutagenic chemicals as a side
effect at 0.2 mg/kg dose.
Effect of CP-P on reduced glutathione activity of non-
enzymatic antioxidant
Non-enzymatic antioxidants are also involved in the tumor
reduction after the treatment with CP-P (Tables 1). GSH plays a
vital role in tissue repair. The combination of CP-P+CYC that was
also influenced higher levels of GSH after 3 weeks treatment when
compared to normal controls (group I). In group II, BCC rats
treated with CP-P or CYC alone (after 20 days) exerted a similar
effect on the enzyme levels like the untreated BCC rats. However,
the CYC-treated rats showed severe toxicity at 0.2 mg/kg
concentrations (group IV), as a result of which potential reduction
in enzyme levels were found. The vitamin C content was
drastically reduced after 90 days (13 weeks) in the BCC rats by
the direct effect of DMBA during the carcinogenic processes.
However, the CP-P alone treated rats (group III) had the most
significantly elevated levels of vitamin C versus the combination of
CP-P+CYC treated rats.
Effect of CP-P on vitamin E (a-Tocopherol) levels
Vitamin E is a naturally occurring compound known as
tocopherols and tocotrienols. In this study, the vitamin E levels
were reduced tremendously by DMBA in untreated BCC rats
(group II). Group III treated with CP-P (0.2 mg/kg) showed
significant elevated levels of vitamin E. More interestingly, the
combination (0.1 mg/kg of CP-P+CYC each) treated rats (group
V) greatly increased the vitamin E levels versus BCC control.
Additionally, CYC (0.2 mg/kg) treated groups (IV) also exerted
the higher level of vitamin E content. There was a gradual
reduction of vitamin content due to the toxic side effects by CYC
following 20 days treatment.
Discussion
In the present study, we investigated the effects of a natural
protein product (CP-P) as a complementary therapy in DMBA-
induced mammary tumorigenesis model. First, we found a
significant in vitro cytotoxic activity of CP-P, with or without
P alone, or with CYC treatment to observe morphological changes. Electron micrographs of MCF-7 cells, (i) untreated control MCF-7 cells which
showed normal morphology. (ii) Calotropis procera protein (CP-P) treatment exhibited cell death at 100 mg/ml concentrations, a portion of the
nucleus dismantled within the cytoplasm and a large number of vacuoles were clearly visible in proteins treated cells. (iii) CYC alone treatment caused
blebbing as revealed by the presence of large vacuoles on MCF-7 treated cells. (iv) These results further confirmed that the combination treatment of
CP-P+CYC induce MCF-7 cells death at 12.5 mg/ml doses. MCF-7 cells treated with CP-P+CYC showed apoptotic morphology including chromatin
condensation into dense granules or blocks. The cells showed loss of microvilli and blebbing of cell membrane which are characteristics of cells
undergoing apoptosis.
doi:10.1371/journal.pone.0048514.g002
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CYC, in breast cancer cell lines MCF-7 and MDA-MB-231.
Second, we also found that CP-P induced significant apoptotic
effects in MCF-7 cells, with or without CYC, which may account
for its potential anti-cancer effects. Third, we also observed that
CP-P suppressed NF-kB activation induced by TNF-a leading to
the suppression of IkBa phosphorylation and degradation. We
also observed that the suppression of TNF-a-induced IKK
activation leads to the inhibition of IkBa phosphorylation and
degradation in MCF-7 cells. CP-P also down-regulated the
expression of various NF-kB-dependent gene products involved
in cell proliferation (e.g. cyclin D1), and anti-apoptosis (e.g. Bcl-2).
Several lines of evidence support the fact that NF-kB plays an
essential role in the development and progression of breast cancer.
First, studies have suggested the presence of constitutively active
NF-kB at an early stage of neoplastic transformation of mammary
cells [48]. Second, NF-kB activation can inhibit apoptosis in
mouse mammary epithelia [49]. Third, selective activation of NF-
kB subunits has been found in human breast cancer cell lines and
in patient samples [50]. Fourth, inhibition of NF-kB in breast
cancer cells can induce spontaneous apoptosis [51]. Also, it has
been shown that the breast cancer tissue of women not responding
to chemotherapy expresses constitutively-active NF-kB [52]. Thus,
inhibition of NF-kB activation by CP-P may account for its anti-
proliferative, pro-apoptotic and chemosensitizing properties as
described here.
Additionally, we also observed the potential inhibitory effects of
CP-P on the development of DMBA-induced breast cancer in rats.
The 0.2 mg/kg dose of CP-P alone treated animals showed only
60.5% inhibition or reduction of tumor. A 0.2 mg/kg dose of
CYC alone treated animals displayed at least 70% tumor
reduction whereas the combination of CP-P (0.1 mg/kg)+CYC
(0.1 mg/kg) treatment caused 74.5% reduction of tumor and
effectively inhibits DMBA-induced tumors in rats. A single dose of
DMBA induces mammary tumors in approximately 90 to 95% of
female Sprague-Dawley (SD) rats [11], [53], [54]. In our study, all
the SD rats developed breast carcinomas after 90 days (13 weeks)
that was confirmed by histopathological examination. Our results
corroborate in part with the previous report, in which an alkaloid
obtained from Solanum pseudocapsicum (2.5 mg/kg doses) showed
similar antitumor activity with increased survival time of tumor-
bearing rats [55]. However, this treatment regimen caused
significant reduction in the body weight due to toxicity, but no
toxicity was observed among CP-P treatment in SD rats in our
experiments.
Histopathological examination confirmed that the normal
control rats displayed normal neoplasm, the CYC treated group
showed low grade differentiation demonstrated by giant multinu-
cleated cells, infiltration of tissues and necrotic effects due to CYC
on rats as well as decreased cell density, infiltration, higher level of
fibrosis, reduction of inflammation, faster neovascularization, non-
invasiveness of tissue architecture observed in CP-P treated rats.
However, the combination of CP-P+CYC treated group V showed
glandular structures, an indication of functional differentiation due
to maximal proliferative rates in the vasculature and epithelium as
a result of antitumor effect. These data suggest that combination
treatment prevents tumor progression significantly. As a result, the
total number and volume of tumors per rat was decreased in the
treated groups. In our previous study, pathological changes
confirm the formation of tumor tubules and neovascularization
after treatment [53].
Furthermore, the activities of enzymatic and non-enzymatic
anti-oxidants were examined in the liver and mammary glands
before and after 3 weeks treatment. CP-P treated groups (III, oral
0.2 mg/kg for 20 days) showed significantly (P,0.01*) elevated
levels of SOD. The combination (CP-P+CYC)-treated group V
exerted significant changes in the enzyme SOD levels than the
CYC alone-treated rats. Glutathione S-transferases (GSTs) are a
family of isoenzymes that play an important role in protecting cells
from cytotoxins and carcinogens [56], [57]. In addition GSTs can
bind and sequester intracellular toxins as well as prevent oxidative
damage by an intrinsic organic peroxidase activity that converts
toxic peroxidase to inactivated alcohols [58], [59]. In this study,
we found that the CP-P treated group showed significantly higher
levels of GSTs than the combination treated group. The GSH
levels were significantly reduced in BCC control groups. The
combination treatment (CP-P+CYC) also induced higher GSH
levels 3 weeks following the treatment. However, the CYC
treatment alone showed a significant increase in GSH levels than
the BCC groups.
We also observed that in the BCC-group, the vitamin C content
was drastically reduced after 90 days (13 weeks) due to carcinogen
exposure. Whereas, in the CP-P administered group (III), a
significant increase in vitamin C levels were noted, which may also
account for its potential anti-cancer effects. Interestingly, it has
been reported previously that the intake of vitamin C significantly
reduces the incidence and growth of mammary tumors, and
therefore has strong potential as a useful therapeutic for inhibiting
breast cancer development [60].
Figure 3. The number of apoptotic cells in breast tumor sections was detected by TUNEL assay. (A) The apoptotic effect of CP-P alone or
in a combination of CYC treatment was analyzed by flow cytometry to compare the various cell cycle phases. The CP-P alone, or in combination with
CYC, induced promising apoptotic effects. As a result, fewer MCF-7 cells accumulated in the Sub-G1 phase compared to the control. (B) TUNEL
positive cells were quantified, revealing that apoptotic cells in breast tumors increased significantly in CP-P or CYC drug alone, or in combination,
groups versus untreated cells. CP-P and CYC drug-treated groups were compared to breast cancer control groups. The combination treatment
induced more positive cells than others. Values are mean 6 S.D. (n = 3) replicates, **P,0.01 values indicate significance to control. (C) CP-P inhibits
TNF-a -induced nuclear degradation/phosphorylation of IkBa. MCF-7 cells were either untreated or pretreated with 50 mg/ml CP-P for 6 h at 37uC and
then treated with 1 nM TNF-a for 30 min. Cytoplasmic extracts were prepared and analyzed by Western blotting using antibodies against anti- IkBa
and phospho-specific IkBa. The same membrane was reblotted with GAPDH antibody to verify equal loading. The results shown are representative of
two independent experiments. (D) CP-P inhibits TNF-a-induced nuclear phosphorylation/translocation of p65. MCF-7 cells were either untreated or
pretreated with 50 mg/ml CP-P for 6 h at 37uC and then incubated with 1 nM TNF-a for 30 min. Nuclear extracts were prepared and analyzed by
Western blotting using antibodies against anti-p65 and phospho-specific p65. The same membrane was reblotted with PARP antibody to verify equal
loading. The results shown are representative of two independent experiments. (E) Effect of CP-P on TNF-induced phosphorylation of IKK-a and IKK-b.
MCF-7 cells were incubated with 50 mg/ml CP-P for 6 h at 37uC and then treated with 1 nM TNF-a for 15 min. Whole cell extracts were prepared and
analyzed by Western blot analysis using anti-phospho-specific IKK-a/b antibody. The same membrane was reblotted with anti-IKK-a antibody to
verify equal loading. (F) CP-P inhibits TNF-a -induced expression of NF-kB-dependent proliferative and antiapoptotic proteins. MCF-7 cells were
incubated with 50 mg/ml CP-P for 6 h at 37uC and then treated with 1 nM TNF-a for 24 h. Whole-cell extracts were prepared and analyzed by Western
blot using the indicated antibodies (Cyclin D1 and Bcl-2). The same membrane was reblotted with b-actin antibody to verify equal loading. Results are
representative of two independent experiments.
doi:10.1371/journal.pone.0048514.g003
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Additionally, we also observed that vitamin E levels were
significantly reduced by DMBA in BCC rats. Interestingly, CP-P
treated rats also had increased vitamin E levels, which may also
account for the observed anti-proliferative effects of CP-P. CP-P
also increased the hepatic UDP-glucuronosyltransferase (UDP-
GT) and glutathione-s-transferase (GST) activities. There was a
decrease in the mammary DNA-DMBA adducts under the same
treatment regimen that led to suppression of DMBA-induced
mammary carcinogenesis. In addition, the combination treatment
induced an apoptotic effect evidenced by TUNEL staining and
significantly decreased the expression of cyclin D1 and Bcl-2 in
breast tumor tissues.
Conclusions
Results from this study confirm that CP-P has potential
anticancer activity which is mainly attributed to its effect on the
proliferation, apoptosis and redox status in breast cancer cells.
Anticancer action occurs through the inhibition of the NF-kB
activation cascade. Further studies are warranted to elucidate the




Phosphotungstic acid, thiobarbituric acid, trichloroacetic acid,
acetic acid, sodium salicylate, and ethylenediaminetetraacetic acid
were purchased from Hi-media Chemicals (Pvt) Ltd, Mumbai,
India. Reduced Glutathione and 5, 59Dithiobis (2-nitrobenzoic
acid (DTNB), carcinogen 7, 12-Dimethylbenz(a)anthracene
(DMBA), and b-actin antibody were purchased from Sigma
Chemicals Co (St. Louis, MO, USA). Ascorbate, iron (III) chloride
(FeCl3), sodium tungstate, sodium nitrate, methanol (Merck,
Germany) and other reagents were of analytical grade. The drug
cyclophosphamide (CYC) was obtained from the Apollo pharma-
cy, Chennai-600034. Antibodies against p65, p50, IkappaBalpha
(IkBa), cyclin D1, B-cell lymphoma 2 (Bcl-2), glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), IkappaB kinase alpha
(IKKa), and poly (ADP-ribose) polymerase (PARP) were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-
specific anti-IkBa (Ser32), phospho-specific anti-p65 (Ser536), and
phospho-specific IKKa/b (Ser-180/181) were purchased from
Cell Signaling (Beverly, MA, USA).
Collection and identification
Root-bark of C. procera (CP) was collected in Thiruthani,
Thiruvalluvar district, Tamil Nadu, India and properly identified
[61]. A voucher specimen was prepared and stored at the institute.
The fresh root-bark was separated, cut into small pieces by using a
sterile razor blade and shade dried at 31uC (room temperature).
This is a very commonly available medicinal plant and no specific
permits were required for the described field studies. It is also
confirmed that the location of the plant collection area is not
privately-owned or protected. Additionally, field studies did not
involve any endangered or protected plant species.
Purification of antitumor protein
The root-bark extract was used for purifying antitumor protein.
The dried material was powdered with an electric blender.
Powdered material (50 g) was suspended in 250 ml of 50 mM
Tris-hydrochloric acid buffer (pH 7.4), and the suspension was
centrifuged at 250 g at 4uC for 15 min. Aliquots (5 ml) of the
brownish clear supernatant were applied on a Superdex G-75
column (1.6640 cm; Amersham Pharmacia, Sweden) previously
equilibrated and eluted with the same buffer. Fractions (2 ml each)
were collected at a flow rate of 12 ml/h. Absorbance of all
fractions was monitored at 280 nm. Five fractions (CP-1, CP-2,
CP-3, CP-4, and CP-5) were collected from the single pool of clear
CP supernatant fractionated on the Superdex column, with
aliquots taken for protein measurement. The CP-3 fraction with
highest protein content and antitumor activity was further purified
by reverse-phase high-performance liquid chromatography (C18,
RP-HPLC) into two peaks (CP-F1 and CP-F2). The CP-F1
fraction was further separated by a C8 column (Jupitor Phenomex)
in 0.1% aqueous trifluoroacetic acid (TFA) (Sigma Co, USA), and
eluted with a linear gradient of 80% acetonitrile (ACN) in 0.1%
TFA. These fractions were monitored at 215 nm [62], [63]. Total
protein in the entire above fractions was estimated using the
Bradford [64] reagent (Bio-Rad, Hercules, CA, USA) before
immediate processing or storage at 280uC.
Mass spectrometry analysis
Analyses were performed primarily using a perspective biosys-
tem matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF/MS) Voyager-DETM mass spectrometer operated
in delayed extraction mode. The biologically active fraction was
analyzed using a saturated solution of a-cyano-4-hydroxycinnamic
acid (Sigma Co, St Louis, MO, USA) in acetone containing 1%
TFA. The active fraction was selected in the mass range of 1–
70 kDa. Spectra were calibrated using the sequazyme mass
standards kit (Perspective Biosystems, Framingham, MA). The
database search program for mass [MS-Fit], was used in National
Center for Biotechnology Information (NCBI) and matrix science
mascot was used in the matrix science-help-sequence database
(MSDB). MALDI-TOF mass spectrometry was used for molecular
mass determination.
Cell line and cell culture
Human breast cancer cell lines MCF-7 and MDA-MB-231
were obtained from the American Type Culture Collection
(Manassas, VA, USA). The cells were cultured under standard
tissue culture conditions and tested negative for mycoplasma
contamination. The cells were maintained in Roswell Park
Memorial Institute (RPMI) 1640 medium (Gibco, Grand Island,
NY, USA), supplemented with 10% w/v fetal bovine serum (FBS)
(Gibco), 1 mM sodium pyruvate, penicillin (100 units/ml) and
streptomycin (100 units/ml) (Gibco) in a 5% CO2 incubator at
37uC. Serum-free medium was used for the above experimental
conditions. The cells were grown up to 80% confluence prior to an
experiment.
Figure 4. Antitumor effect of CP-P (0.1 mg/kg, oral administration)+CYC (0.1 mg/kg, intra peritoneal injection) treated on DMBA-
induced mammary tumors in rats after 110 days. (A) Microscopic images showed that the DMBA-induced breast tumor development after 90
days on either side of the mammary gland are marked by a circle and an arrow pointed out. (B) Breast tumor volume was measured and calculated as
30 millimeter in diameter in breast cancer control panel and the tumor incidence was compared within the groups. (C) Percentage reduction of
tumor volume was measured after 20 days treatment of CP-P (0.1 mg/kg, oral administration)+CYC (0.1 mg/kg, intra peritoneal injection). (D) Body
weight loss before and after the treatment. Body weight changes of different treatments compared within the five different groups (Symbol denotes:
NC-Normal Control, BBC - Breast Cancer Control).
doi:10.1371/journal.pone.0048514.g004
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Assay for cytotoxicity
The antiproliferative effect of CP-P against MCF-7 and MDA-
MB-231 cells was determined by the 3-(4, 5-Dimethylthiazol-2-yl)-
2, 5-diphenyltetrazolium bromide (MTT, Sigma Chemicals Co,
St. Louis, MO, USA) dye uptake method as described previously
[65]. Briefly, cells (106/ml) were incubated in triplicate in a 96-well
plate with or without different concentrations of CP-P or CYC
alone, or in combination (800–12.5 mg/ml) in a final volume of
Figure 5. Histopathological examination of mammary tumor tissues. (A) Normal histology of breast tissue consisting lobules (l),
myoepithelial (me), ductal hyperplasia (dh) with basement membrane. (B) Carcinoma of the rat mammary gland with extensive solid areas in small
cluster. (C) Highly invasive (iv) tumor cells surrounding residual area and expanding into the adjacent stroma. Inhibitory potential of CP-P alone or in
combination with CYC on DMBA-induced mammary tumors. (D) CYC inhibited the formation of lobular hyperplasia (lh) that is precursor to invasive
disease. (E) The combination of CP-P+CYC treatment significantly reduced the number of inflammatory cells, hyperplasia and dysplasia respectively
(Magnification 620). Symbol denotes: lo-lobules, me-myoepithelial, dh-ductal hyperplasia, iv-invasive solid areas, lh-lobular hyperplasia, ne-
neovascularization. (F) CP-P inhibits expression of NF-kB-regulated gene products in breast cancer tissue samples. Western blot analysis showed the
inhibition of the expression of Cyclin D1 and Bcl-2 by CP-P in whole cell extracts obtained from tumor tissues.
doi:10.1371/journal.pone.0048514.g005
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0.2 ml for indicated time intervals at 37uC. Thereafter, MTT
(20 ml of 5 mg/ml in PBS) was added to each well. After a 2 h
incubation at 37uC, 0.1 ml lysis buffer (20% SDS, 50% dimethyl-
formamide) was added; incubation was continued overnight at
37uC and optical density (OD) at 490 nm was measured by a
BenchMark Plus plate reader (BioRad Laboratories, Hercules,
CA, USA). The percent of cytotoxicity was calculated by
comparing with the untreated control.
Lactate dehydrogenase (LDH) release assay
The lactate dehydrogenase (LDH) release into media was an
indicator of cell death detected according to the manufacturer’s
instructions (Roche, Indianapolis, USA). Briefly, after incubation,
200 ml of cell medium was transferred to a sterile 96-well plate
with 50 ml of LDH reagent. After the reaction, the brownish red
color development was measured at 440 nm by ELISA reader
(Bench Markplus, Bio-Rad, CA, USA). Results are expressed as
the percentage of LDH release versus control cells [66].
Morphological changes of MCF-7 cells as determined by
Transmission Electron Microscopy (TEM)
TEM of CP-P alone, or in a combination with CYC, treated
MCF-7 cancer cells were performed as previously described [54].
Cells (26105 cells/ml) were seeded onto sterile cover glass. Cells
were initially fixed in 2.5% glutaraldehyde followed by post-
fixation with 1% osmium tetroxide. Samples were then dehydrated
with an ascending series of ethyl alcohol baths (50–100%) before
subsequent embedding in araldite resin. Semi- and ultra-thin
sections were cut using a glass knife. The ultrathin sections were
doubly stained with uranyl acetate and lead citrate before viewing
under an Olympus EM2085 microscope (Philadelphia, PA, USA).
Cell cycle analysis
The phases of cell cycle distribution following CP-P alone, or in
combination with CYC, treatment of MCF-7 cells were analyzed
after propidium iodide (PI) staining by flow cytometry [67].
Control and treated (IC50 dose, 24 h) MCF-7 cells were spun out
of culture medium, washed with cold PBS, and fixed in 70%
ethanol. The cells were then washed again, treated with DNase-
free RNase A (10 mg/ml) at 37uC for 30 min, and stained with PI
(200 ml from 50 mg/ml) for 15 min at 37uC. Cell cycle phase
distribution of nuclear DNA was measured in a FACS caliber
single laser flow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA) using a 488 nm argon laser light source and 623 nm band
pass filter using Cell Quest software (n = 4).
Western blot analysis
To determine protein expression levels, we prepared extracts
and fractionated them by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) as described previously [68]. After electrophoresis,
the proteins were electrotransferred to a nitrocellulose membrane,
blocked with 5% nonfat milk to minimize non-specific binding,
and probed with protein-specific antibodies (1:3000) overnight at
4uC. Blots were washed, exposed to HRP-conjugated secondary
antibodies for 2 h, and the expression of various proteins was
detected by chemiluminescence emission (ECL; GE Healthcare,
Little Chalfont, Buckinghamshire, UK).
Terminal transferase dUTP nick end labeling (TUNEL)
assay
Activation of endonucleases that cleave chromosomal deoxyri-
bonucleic acid (DNA) is a hallmark of apoptosis. DNA fragmen-
tation revealed by a multitude of DNA strand breaks, therefore, is
considered the gold standard for identifying apoptotic cells.
Several methodologies are based on fluorochrome-labeling of 3-
OH termini of DNA strand breaks in situ with the use of exogenous
terminal deoxynucleotidyl transfer (TdT). This is commonly
defined as the TUNEL assay [69]. MCF-7 cells (106 cells/well)
were grown in a 96-well plate and exposed to CP-P or CYC alone
or in combination, for 24 h. Cells without treatment served as
controls. Cells were fixed with 4% paraformaldehyde for 10 min.
After fixation at room temperature, cells were washed twice with
PBS for 5 min each and then incubated with 3% hydrogen
peroxide (H2O2) to block endogenous peroxidase activity. After
10 min, the cells were incubated in the labeling reaction mixture
containing TdT at 37uC for 1 h. The reaction was terminated by
adding stop buffer and cells were washed 3 times with PBS for
2 min each. Cell nuclei were counterstained with Hoechst 33342












Superoxide dismutase1 4.1660.51 1.6060.27 a* 2.7560.81 b* 2.8060.28 b* 4.0060.72 a1 b*
Catalase2 48.8560.51 29.6662.05 a* 31.3362.27 b1 36.6563.22 b* 46.2163.2 aNS b*
Glutathione-s-transferase3 1.3360.13 0.9760.17 a* 1.0360.21 b1* 1.1060.11 b* 1.2960.14 aNS b*
Reduced glutathione4 3.0860.34 1.8360.27 a* 2.0860.23 bNS 2.6160.28 b* 2.9860.14 aNS b*
Vitamin C5 1.5860.51 0.7860.09 a* 0.9160.15 b* 0.9660.076 b* 1.4760.13 aNS b*
Vitamin E6 18.2061.713 9.1461.96 a* 12.0661.02 b* 12.2261.02 b* 16.8361.16 a1b*




NS - Not Significant (with respect to control), Abbreviations: NC - normal control, BCC - breast cancer control, BC - breast cancer, CYC - cyclophosphamide, CP-P -
Calotropis procera protein, (a) - Group II and IV compared between Group I, (b) - Group III, IV and V compared between Group II.
1units/mg protein required to inhibit 50% of adrenaline autooxidation,
2m moles of H2O2 consumed/min/mg protein,
3mg of thio ester formed/min/mg protein,
4mg of GSH/mg protein,
5 & 6mg/g wet tissue.
doi:10.1371/journal.pone.0048514.t001
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(Sigma-Aldrich Co, St. Louis, MO, USA) and mounted upon a
cover slip with Dako fluorescent mounting medium. Cells were
observed under fluorescence microscope (Olympus Corporation,
Center Valley, PA, USA).
In vivo anticancer effect of CP-P in rats
Six week old female Sprague Dawely rats (250–300 gm body
weight) were obtained from the National Institute of Nutrition,
(Hyderabad-500 007, India) and divided into five groups (n = 5 per
group), rats subsequently maintained in a controlled condition
including 12 h light and 12 h dark cycles. Standard diet and tap
water was ad libitum. The experiment was conducted according to
the guidelines of the Institutional Animal Ethical Committee for
Experimentations on Animals (IAECEA), and approved by the
University of Madras, India. Group I served as a normal control
animals (NC), group II - breast cancer bearing-animals treated
with saline served as the breast cancer control (BCC), group III -
breast cancer-bearing animals treated with CP-P alone (0.2 mg/
kg, oral), group IV - breast cancer-bearing rats treated with CYC
alone 0.2 mg/kg, i.p) and group V - breast cancer-bearing animals
treated with CP-P (0.1 mg/kg, oral)+CYC (0.1 mg/kg, intraper-
itoneal¸ i.p.). Induction of breast cancer: 1 mg of DMBA was
dissolved in 0.5 ml of sunflower oil and 0.5 ml saline injected by
subcutaneous injection beneath the mammary gland on either side
(group II–V). The solid tumor developed after 90 days. After 13
weeks, the breast tumor-bearing rats were treated for 20 days [54],
[70], [71].
Histopathological examination of tumor tissues
Macroscopic mammary tumors, fixed in 10% buffered formalin,
were embedded in paraffin using a conventional automated
system. The blocks were cut to obtain 5 mm thick sections and
stained with hemotoxylin-eosin (H & E) for histological examina-
tion [71]. Serial paraffin sections of each tissue image were
captured by light microscopy (Olympus BX51, Philadelphia,
USA).
Breast tissue homogenate for biochemical analysis
The overnight-fasted animals were sacrificed by cervical
decapitation; breast tissues were excised and quickly removed.
The tissue (50 mg) was washed thoroughly with chilled PBS, cut
into small pieces with a sterile heavy-duty blade, and finally
homogenized on ice. The homogenate was centrifuged at
10,000 rpm for 15 min and supernatant diluted with PBS to a
final concentration of protein (30 mg/ml). The biochemical anlysis
of enzymatic antioxidant such as superoxide dismutase, catalase,
glutathione-s-transferase, and non-enzymatic antioxidants such as
reduced glutathione, vitamin C and E were estimated in the
treated and untreated breast tissues of control rats.
Superoxide dismutase (SOD) radical scavenging activity
Superoxide activity was assessed by the nitroblue tetrazolium
(NBT) reduction method [72]. Test materials ranging from 1–
150 mg/ml were added into reaction mixtures containing 0.1 mM
EDTA (200 ml), 0.12 mM riboflavin (50 ml) and 0.6 M phosphate
buffer (pH 7.8) in a final volume of 3 ml. Optical density was
determined at 560 nm.
Estimation of glutathione-s-transferase (GST) activity
Glutathione-S-transferase was assayed by the method described
by Habig et al, [73]. The tissue samples were homogenized with
10 ml of 1-chloro-2, 4-dinitrobenzene (CDNB) phosphate buffer
(0.5 M pH 6.5) and centrifuged at 12,000 rpm for 10 min. The
supernatant was made up to 2.5 ml with double distilled water.
The reaction mixture was pre-incubated at 37uC for 5 min. GSH
(0.1 ml) was added and absorbance was measured at 340 nm for
3 min intervals. The enzyme activity was expressed as mg of
thioester formed/min/mg protein of tissue.
Determination of catalase (CAT) activity
The catalase activity was determined spectrophotometrically
according to the method described by Johansson and Borg, [74].
Tissue (50 mg) was homogenized in 1.0 ml of phosphate buffer
(50 mM, pH 7.0) and centrifuged at 10,000 rpm for 10 min.
Hydrogen peroxide (H2O2) 0.4 ml was added to the supernatant.
The reaction was stopped at 15, 30, 45 and 60 seconds by adding
0.2 ml of dichromate acetic acid. Tubes were boiled for 10 min,
cooled and read at 620 nm. The standards for H2O2, ranging from
20–100 mm, were processed as above. Catalase activity was expressed
as mmoles of H2O2 decomposed/min/mg of tissue protein.
Estimation of reduced glutathione (GSH) activity
Glutathione peroxide was assayed by the method described by
Forstrom et al, [75]. 0.2 ml each of EDTA (2.34 mg/ml of sodium
azide), glutathione reduced (GSH) 3 mM (12.29 mg of GSH was
dissolved in 10 ml of water. Hydrogen peroxide (2.5 mM, 0.085 ml
of H2O2 was made up to 10 ml with double distilled water).
Phosphate buffered solution (0.3 mM) and 50 mg of tissue
homogenate or lysate were mixed and incubated at 37uC for
10 min. The reaction was arrested by adding 0.5 ml of trichlor-
oacetic acid (TCA) (10%) and tubes were centrifuged 0.5 ml of
supernatant. 0.3 ml of phosphate solution and 1.0 ml of DTNP-2,29-
dithiobis-(5-nitropyridine) (6 mM), 40 mg of DTNB dissolved in
100 ml of 1% trisodium citrate was added and colour development
was read at 420 nm using a spectrophotometer. Glutathione activity
was expressed as mg glutathione utilized/min/mg protein.
Estimation of vitamin C (Ascorbic acid) levels
Ascorbic acid level was estimated by the method described by
Omaye et al, [76]. Breast tissue homogenate 0.5 ml was mixed with
0.5 ml of distilled water and 0.1 ml of 5% TCA were added, mixed
thoroughly and centrifuged at 1500 rpm for 20 min (4uC). Super-
natant (1 ml) was mixed with 0.2 ml of dithiocarbonate (DTC)
reagent and incubated at 37uC for 3 h. 1.5 ml of 65% sulphuric acid
was added andmixed well. The solution was allowed to stand at room
temperature for another 30 min, and absorbance read at 520 nm.
The graded amount of standards was also carried out similarly. The
ascorbic acid level was expressed as mg/g of fresh tissue.
Estimation of vitamin E (a-Tocopherol)
Vitamin E level was determined by the method described by
Gupta et al, [77] with slight modifications. Tumor tissues (100 mg)
were weighed and homogenised with 1.5 ml of buffer solution.
The tissue homogenate was put into 5 screw capped centrifuge
tubes and centrifuged at 10,000 rpm for 15 min (4uC). 1.5 ml of
xylene was then added to all tubes and shaken well. After
centrifugation, 0.1 ml of the xylene layer was taken and 1.0 ml of
dipyridyl reagent added, mixed well and read at 460 nm against
the blank (1.5 ml distilled water) using a spectrophotometer.
Afterwards, 0.33 ml of ferric chloride reagent was added to all
tubes incubated for 90 min. The test and standards were read at
520 nm against the blank using a spectrophotometer.
Statistical analysis
Statistical comparisons between control and treatment mean
values of two parameters were analyzed using the Student’s t-test.
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Multiple comparisons were done using ANOVA. The differences
were statistically significant at *P,0.01; **P,0.05 levels.
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